Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Medicine (Baltimore) ; 103(32): e39238, 2024 Aug 09.
Article in English | MEDLINE | ID: mdl-39121264

ABSTRACT

The role of human microbiota in mental health and the underlying mechanisms of psychobiotics, which can modulate mood and behavior through the microbiota-gut-brain axis, has been a focus of scientific scrutiny. This work presents a bibliometric analysis to uncover research trends and insights in psychobiotics literature. The Clarivate Analytics Web of Science database served as the source for articles and reviews on psychobiotics spanning the years 2012 to 2023. Bibliometric network visualization and graphing were conducted using VOSviewer, Microsoft Excel for Windows 10, and Datawrapper software. A total of 348 publications were included, and it has been determined that the number of publications and citations shows an increasing trend from 2012 to 2023. The most active authors on psychobiotics, in order, were Dinan TG, Cryan JF, and Tsai YC. The most active organizations have been identified as University College Cork, National Yang Ming Chiao Tung University, and Bened Biomedical Co. Ltd. The most active countries in psychobiotic research were China, Ireland, and United States of America, while the most active journals were Nutrients, International Journal of Molecular Sciences, and Probiotics and Antimicrobial Proteins. The most commonly used keywords were "psychobiotics," "probiotics," and "gut-brain axis." This bibliometric analysis has revealed the growing academic interest in psychobiotics, indicating that the relationship between gut microbiota and mental health will increasingly be supported by scientific evidence in the years ahead.


Subject(s)
Bibliometrics , Probiotics , Humans , Gastrointestinal Microbiome , Affect , Brain-Gut Axis , Mental Health
2.
Biomed Res Int ; 2020: 2123601, 2020.
Article in English | MEDLINE | ID: mdl-32964020

ABSTRACT

Maintaining regular blood pressure control usually requires multidrug regimens rather than monotherapy. The objective of this study was to describe the effectiveness and safety of an angiotensin-converting enzyme inhibitor and a nondihydropyridine calcium channel blocker in a single-tablet combination in patients with hypertension, a heart rate higher than 70 beats/min, and type 2 diabetes mellitus (T2DM). This study was conducted in Turkey as a prospective, noninterventional, observational study. At 22 clinical sites, the data of 200 patients with hypertension were used for efficacy analysis; however, 262 patients received at least one dose of trandolapril/verapamil fixed-dose combination at two dose strengths. Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, PR interval, glycated haemoglobin (HbA1c), and albumin/creatinine ratios were recorded during 8 weeks of treatment. With treatment, the mean (±SD) SBP that was recorded as 162.8 (±14.642) mm Hg at baseline was reduced to 131.7 ± 11.1 mm Hg at week 8 (p < 0.05). Similarly, the mean DBP was reduced from 93.76 ± 9.16 mm Hg to 77.6 ± 7.6 mm Hg (p < 0.001). Following 8 weeks of treatment, SBP and DBP values were reduced below 140 mm Hg and 90 mm Hg in most patients (81.5%), respectively. The mean heart rate as evaluated using electrocardiography measurements was reduced to 78.25 beats/min at week 8 as compared with baseline during trandolapril/verapamil single-pill combination treatment (p < 0.001). Treatment with trandolapril and verapamil was well tolerated over 8 weeks with no unexpected safety signals. In conclusion, the single-pill combination of trandolapril and verapamil was considered effective in reducing and controlling blood pressure in patients with hypertension and T2DM. There was a significant improvement in HbA1c and ACR levels in a smaller subgroup of the patient cohort. The trandolapril/verapamil combination was evaluated as being safe and well-tolerated following a treatment period of 8 weeks. This trial was registered with NCT02298556.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Calcium Channel Blockers/therapeutic use , Diabetes Mellitus, Type 2/drug therapy , Hypertension/drug therapy , Indoles/therapeutic use , Verapamil/therapeutic use , Blood Pressure/drug effects , Drug Combinations , Female , Heart Rate/drug effects , Humans , Male , Middle Aged , Prospective Studies , Turkey
3.
Clin Lab ; 62(3): 401-8, 2016.
Article in English | MEDLINE | ID: mdl-27156330

ABSTRACT

BACKGROUND: Colorectal cancer (CRC) is the third most common cause of cancer diagnosed in males and the second in females. Survival is strongly related to stage at diagnosis. There is an urgent need to find a noninvasive biomarker that can be commonly applied for screening diagnosis, early detection of recurrence, and monitoring of metastatic CRC. Protein caveolin-1 (CAV-1) has been known to be expressed abnormally in colon cancer and appears to contribute to aberrant signaling and protein trafficking. There are controversial results regarding the role of CAV-1 in cancer. We hypothesized that levels of CAV-1 in serum of patients with CRC might be important to estimate the progression of the disease. Therefore, the purpose of this study is to investigate whether serum CAV-1 might be used as a factor determining progression of CRC. METHODS: A total of 61 patients with CRC (26 male, 35 female) and 46 controls (38 male, 8 female) were enrolled. Serum CAV-1 levels were measured by ELISA. The relationship between CAV-1 and progression-free survival (PFS) was analyzed with use of receiver operating characteristic (ROC) and Kaplan-Meier analysis. Results were given as median (95% CI). Mann-Whitney test was used for the comparison of groups. RESULTS: CAV-1 levels were found to be 11.5 ng/mL (10.4-12.9) in CRC and 11.9 ng/mL (10.7-14.4) in controls (p = 0.465). The serum CAV-1 levels in CRC patients with disease progression and without progression were respectively 10.0 ng/mL (8.5-11.3) and 12.2 ng/mL (11.1-14.8) (p = 0.023). In ROC analysis, if CAV-1 levels are equal or lesser than 10.73 ng/mL, it might show presence of progression with a sensitivity 73.3% and specificity 66.7% in patients with CRC (area under the ROC curve (AUC) = 0.697, p = 0.005). The mean PFS time was found to be 29.7 months (19.8-39.7, 95% CI for the mean) in patients who have CAV-1 level ≤ 10.73 ng/mL and 61.9 months (44.2-79.6) in patients who have CAV-1 level > 10.73 ng/mL [hazard ratios (HR) with 95% CI = 3.49 (1.26 - 9.68) (p = 0.017)]. CONCLUSIONS: Our results strongly suggest that CAV-1 levels might be used as a marker to determine progression of CRC. When considered in combination with other biomarkers of CRC, CAV-1 is clinically informative and instructive.


Subject(s)
Biomarkers, Tumor/blood , Caveolin 1/blood , Colorectal Neoplasms/blood , Aged , Colorectal Neoplasms/mortality , Disease Progression , Female , Humans , Male , Middle Aged
4.
Med Sci Monit ; 21: 2750-6, 2015 Sep 15.
Article in English | MEDLINE | ID: mdl-26371941

ABSTRACT

BACKGROUND: This study aimed to investigate the prevalence of malnutrition and explore the somatic, psychological, functional, and social or lifestyle characteristics linked to malnutrition in elderly people at a hospital in Turkey. MATERIAL AND METHODS: This study included 1030 patients older than 65 years of age who were seen at the internal medicine and geriatrics outpatient clinics of the study centers in Istanbul, Ankara, Duzce, Corum, Mardin, Malatya, and Diyarbakir provinces between January and December 2014. All patients underwent Mini Nutritional Assessment (MNA) and Geriatric Depression Scale (GDS) tests via one-on-one interview method. The demographic properties of the patients were also recorded during this interview. RESULTS: Among 1030 patients included in this study, 196 (19%) had malnutrition and 300 (29.1%) had malnutrition risk. The malnutrition group and the other groups were significantly different with respect to mean GDS score, income status, educational status, the number of children, functional status (ADL, IADL), the number of patients with depression, and the number of comorbid disorders. According to the results of the logistic regression analysis, age (OR=95% CI: 1.007-1.056; p=0.012), BMI (OR=95% CI: 0.702-0.796; p<0.001), educational status (OR=95% CI: 0.359-0.897; p=0.015), comorbidity (OR=95% CI: 2.296-5.448; p<0.001), and depression score (OR=95% CI: 1.104-3.051; p=0.02) were independently associated with malnutrition. CONCLUSIONS: Our study demonstrates that age, depression, BMI, comorbidity, and the educational status were independently associated with malnutrition in an elderly population.


Subject(s)
Malnutrition/epidemiology , Nutritional Status , Activities of Daily Living , Aged , Aged, 80 and over , Cross-Sectional Studies , Depression/diagnosis , Female , Humans , Independent Living , Life Style , Logistic Models , Male , Nutrition Assessment , Risk Factors , Turkey/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL